Elicio Therapeutics (Nasdaq: ELTX) announced on April 16, 2026 that it granted 21,210 inducement stock options to a new employee, approved by the Compensation Committee under the 2024 Inducement Incentive Award Plan.
The options have a $11.78 per-share exercise price (Nasdaq closing price on April 15, 2026) and vest over four years: 25% on the first anniversary of employment, then monthly thereafter, subject to continued service and Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ELTX
+6.96%2.6x vol
16 alerts
+6.96%Session close to close
+13.2%Peak in 27 hr 7 min
$255.52MMarket Cap
2.6xRel. Volume
In the Apr 16 session, ELTX gained 6.96%, reflecting a notable positive market reaction.
Argus tracked a peak move of +13.2% during that session.
Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Trading volume was elevated at 2.6x the daily average, suggesting notable buying interest.
The stock moved +7.0% in the session following this news. A strong positive reaction aligns with the...
Analysis
The stock moved +7.0% in the session following this news. A strong positive reaction aligns with the company’s history of constructive responses to corporate updates, including prior inducement grants and financing steps. With an active shelf for up to $400,000,000 and recent ATM capacity, investors have needed to weigh potential future issuance against clinical and strategic progress, so sharp upside moves could be vulnerable if funding activity accelerates or news flow slows.
Key Figures
Inducement options granted:21,210 optionsOption exercise price:$11.78 per shareVesting period:4 years+3 more
6 metrics
Inducement options granted21,210 optionsAggregate inducement stock options to a new employee on Apr 15, 2026
Option exercise price$11.78 per shareGrant price equal to Nasdaq closing price on Apr 15, 2026
Vesting period4 yearsInducement stock options vest over four years
Initial vesting tranche25% of sharesVests on first anniversary of employee’s start date
Current share price$11.78Pre-news price context from market data
Market capitalization$215,785,948Equity value based on pre-news trading data
Grant of 22,400 inducement options at $7.81 to two new employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, including inducement grants and corporate updates, has often been followed by modestly positive price reactions, suggesting investors have generally responded constructively to routine corporate and clinical disclosures.
Recent Company History
Over the last few months, Elicio has repeatedly reported inducement option grants alongside broader corporate updates. Earlier grants on Jan 15, 2026, Feb 17, 2026, and Mar 16, 2026 all saw small positive next-day moves. Larger reactions followed the full-year 2025 results and a healthcare conference appearance, with double-digit gains after those events. Today’s inducement grant continues the pattern of equity-based hiring within the ongoing 2024 Inducement Incentive Award Plan.
Key Terms
inducement stock options, nasdaq listing rule 5635(c)(4), inducement incentive award plan
3 terms
inducement stock optionsfinancial
"Elicio granted an aggregate of 21,210 inducement stock options to a new employee"
Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement incentive award planfinancial
"granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan"
An inducement incentive award plan is a package of stock-based pay—like options or restricted shares—given to a newly hired executive or key employee to persuade them to join a company. It matters to investors because such awards can spread ownership thinner and create a cost on the company’s financial statements, while also aligning the new hire’s performance with shareholder value much like a signing bonus that ties future pay to company results.
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2026, Elicio granted an aggregate of 21,210 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
The grant provides for the purchase of shares of Elicio common stock at a price of $11.78 per share, the closing price per share of Elicio common stock as reported by Nasdaq on April 15, 2026, the date of grant.
The grant vests over four years, with 25 percent of the shares vesting on the first anniversary of the employee’s start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Elicio intends to expand ELI-002 7P clinical development not only for treatment in adjuvant pancreatic ductal adenocarcinoma, but also in neoadjuvant and metastatic pancreatic ductal adenocarcinoma (“PDAC”) settings, and for other mKRAS-positive cancers. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive PDAC who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.
Investor Relations Contact Brian Ritchie LifeSci Advisors (212) 915-2578 britchie@lifesciadvisors.com
FAQ
How many inducement options did Elicio Therapeutics (ELTX) grant on April 15, 2026?
Elicio granted 21,210 inducement stock options to a new employee. According to the company, the grant was approved by the Compensation Committee and issued under the 2024 Inducement Incentive Award Plan.
What is the exercise price of the ELTX inducement options granted April 15, 2026?
The exercise price is $11.78 per share, equal to the Nasdaq closing price on April 15, 2026. According to the company, that price was set as the grant date fair exercise price for the inducement award.
What is the ELTX inducement grant vesting schedule for the options granted April 15, 2026?
The options vest over four years with 25% vesting on the first anniversary and monthly thereafter. According to the company, vesting is subject to the employee's continued service through each vesting date.
Under what Nasdaq rule were the ELTX inducement options granted on April 15, 2026?
The grant was made as an inducement under Nasdaq Listing Rule 5635(c)(4). According to the company, this rule permits inducement awards for newly hired employees subject to required approvals.
Who approved the ELTX inducement stock option grant dated April 15, 2026?
The Compensation Committee of Elicio's Board of Directors approved the inducement grant. According to the company, the award was granted under the 2024 Inducement Incentive Award Plan.
Will the ELTX inducement grant dilute existing shareholders immediately after April 15, 2026?
The announcement does not state immediate dilution metrics or percent ownership change. According to the company, 21,210 options were granted, but outstanding share totals were not disclosed to quantify dilution.
